SEOM guidelines for cervical cancer

• A. Oaknin ^[9] ; M. J. Rubio ^[8] ; A. Redondo ^[1] ; A. De Juan ^[2] ; J. F. Cueva Bañuelos ^[3] ; M. Gil-Martin ^[4] ; E. Ortega ^[10] ; A. Garcia-Arias ^[5] ; A. Gonzalez-Martin ^[6] ; I. Bover ^[7]
  1. [1] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  2. [2] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  3. [3] Complexo Hospitalario Universitario de Santiago

     Complexo Hospitalario Universitario de Santiago

     Santiago de Compostela, España

     
  4. [4] Hospital Duran i Reynals

     Hospital Duran i Reynals

     Barcelona, España

     
  5. [5] Hospital de Sant Joan Despí Moisès Broggi

     Hospital de Sant Joan Despí Moisès Broggi

     Barcelona, España

     
  6. [6] University of Texas MD Anderson Cancer Center

     University of Texas MD Anderson Cancer Center

     Estados Unidos

     
  7. [7] Hospital Son Llàtzer

     Hospital Son Llàtzer

     Palma de Mallorca, España

     
  8. [8] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  9. [9] Vall d’Hebron University Hospital
  10. [10] Hospital Universitari Arnau de Villanova de Lleida

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 12, 2015, págs. 1036-1042
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cervical cancer (CC) is the second most common cancer worldwide, strongly linked to high-risk human papilloma virus infection. Although screening programs have led to a relevant reduction in the incidence and mortality due to CC in developed countries, it is still an important cause of mortality in undeveloped countries. Clinical stage is still the most relevant prognostic factor. In early stages, the primary treatment is surgery or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. In the setting of recurrent or metastatic CC, for the first time ever, the combination of chemotherapy plus bevacizumab prolongs the overall survival beyond 12 months. Therefore, this regimen is considered by most of the oncologist a new standard of care for metastatic/recurrent CC.